Maurizio Ceppi

Company: Transgene

Job title: Chief Scientific Officer

Seminars:

Personalised Cancer Vaccine TG4050 in Resected Locally Advanced Head & Neck Squamous Cell Carcinoma (HNSCC) Patients 9:30 am

Reviewing TG4050, an individualised immunotherapy being developed for solid tumours that is based on Transgene’s myvac® technology and powered by NEC’s longstanding artificial intelligence (AI) and machine learning expertise Discussing how TG4050 is being evaluated in a randomised multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and…Read more

day: Day Two